Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives-Reference-Cited by-同舟云学术

Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives

Published:2022-10-02 Issue: Volume: Page:
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Tsaur Igor,Blaheta Roman A.,Dotzauer Robert,Brandt Maximilian P.,Gandaglia Giorgio,Sinescu Ioanel,Mirvald Cristian,Olivier Jonathan,Surcel Cristian,Tsaur Igor,Blaheta Roman A.,Brandt Maximilian,Dotzauer Robert,Olivier Jonathan,Gandaglia Giorgio,Surcel Christian,

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://link.springer.com/content/pdf/10.1007/s00345-022-04162-5.pdf

Reference65 articles.

1. Ong S, O’Brien J, Medhurst E, Lawrentschuk N, Murphy D, Azad A (2021) Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review. Transl Androl Urol. 10(10):3918–3930. https://doi.org/10.21037/tau-20-1118

2. Teo MY, Rathkopf DE, Kantoff P (2019) Treatment of advanced prostate cancer. Annu Rev Med 70:479–499. https://doi.org/10.1146/annurev-med-051517-011947

3. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa2119115

4. Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75(3):410–418. https://doi.org/10.1016/j.eururo.2018.09.008

5. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current evidence on local therapy in oligometastatic prostate cancer;Current Opinion in Urology;2024-02-01

2. A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging–Targeted and Systematic Biopsies: A European Multicenter Study;European Urology Focus;2023-11

3. Current Management and Future Treatment Strategies for Patients with Metastatic Hormone-Sensitive Prostate Cancer;World Journal of Urology;2023-07-31